周 宗慶

Medicine & Life Sciences

1. Living Donors 100%
2. Kidney 91%
3. Transplants 74%
4. Nephrectomy 69%
5. Effective Renal Plasma Flow 64%
6. Kidney Transplantation 51%
7. Transplant Recipients 49%
8. Allografts 48%
9. Peliosis Hepatis 37%
10. Hepatocellular Carcinoma 35%
11. Glomerular Filtration Rate 35%
12. Tissue Donors 32%
13. Calcineurin Inhibitors 31%
14. Reticulin 31%
15. Liver Transplantation 30%
16. Splenic Artery 29%
17. Liver 28%
18. Splenectomy 28%
19. Everolimus 27%
20. Renal Artery 27%
21. Antibodies 26%
22. Gallstones 24%
23. Cholecystectomy 24%
24. Tumor Microenvironment 23%
25. Ascites 21%
26. Hydroxymethylglutaryl-CoA Reductase Inhibitors 21%
27. Ligation 19%
28. Liver Diseases 18%
29. Immunosuppressive Agents 18%
30. Enzyme-Linked Immunosorbent Assay 18%
31. Motivation 17%
32. Retrospective Studies 17%
33. Meta-Analysis 16%
34. Hemodynamics 16%
35. Safety 15%
36. Centers for Disease Control and Prevention (U.S.) 15%
37. Warm Ischemia 14%
38. Purpura 13%
39. Hyperbilirubinemia 13%
40. Gene Expression 13%
41. Drug Therapy 13%
42. Odds Ratio 12%
43. Needle Biopsy 12%
44. Capillaries 10%